Comparative Pharmacology
Head-to-head clinical analysis: DAYPRO versus DAYPRO ALTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DAYPRO versus DAYPRO ALTA.
DAYPRO vs DAYPRO ALTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and thereby alleviating pain and inflammation.
Oxaprozin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
600 mg orally once daily; max 1200 mg/day
Oxaprozin is administered orally. The usual adult dose is 1200 mg once daily. For osteoarthritis and rheumatoid arthritis, dosing can range from 600 to 1200 mg once daily. A starting dose of 600 mg once daily may be considered for patients with low body weight or milder disease.
None Documented
None Documented
Approximately 40-70 hours (mean ~50 h), allowing once-daily dosing; steady-state reached in 4-6 days.
50-65 hours (mean 57 hours); clinically significant accumulation occurs with multiple dosing, requiring dose adjustment in elderly and renal impairment.
Renal (approx. 70-80% as unchanged drug and glucuronide conjugate; biliary/fecal excretion accounts for the remainder).
Renal: 85% (60-90% as oxaprozin glucuronide and 5-10% as unchanged oxaprozin); Fecal: <5%; Biliary: negligible.
Category C
Category C
Nonsteroidal Anti-Inflammatory Drug (NSAID)
Nonsteroidal Anti-Inflammatory Drug (NSAID)